β-Defensin-2 Protein Is a Serum Biomarker for Disease Activity in Psoriasis and Reaches Biologically Relevant Concentrations in Lesional Skin-Reference-Cited by-同舟云学术

β-Defensin-2 Protein Is a Serum Biomarker for Disease Activity in Psoriasis and Reaches Biologically Relevant Concentrations in Lesional Skin

Published:2009-03-06 Issue:3 Volume:4 Page:e4725
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Jansen Patrick A. M.,Rodijk-Olthuis Diana,Hollox Edward J.,Kamsteeg Marijke,Tjabringa Geuranne S.,de Jongh Gys J.,van Vlijmen-Willems Ivonne M. J. J.,Bergboer Judith G. M.,van Rossum Michelle M.,de Jong Elke M. G. J.,den Heijer Martin,Evers Andrea W. M.,Bergers Mieke,Armour John A. L.,Zeeuwen Patrick L. J. M.,Schalkwijk Joost

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference51 articles.

1. Getting under the skin: the immunogenetics of psoriasis.;AM Bowcock;Nat Rev Immunol,2005

2. Immunopathogenesis of psoriasis.;BJ Nickoloff;Clin Rev Allergy Immunol,2007

3. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene.;RP Nair;Am J Hum Genet,2006

4. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.;M Cargill;Am J Hum Genet,2007

5. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.;F Capon;Hum Genet,2007

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the Complexity of In Vitro Skin Models: A Review of Cutting-Edge Developments;Journal of Investigative Dermatology;2024-08

2. Biomarkers in Psoriasis: The Future of Personalised Treatment;Indian Journal of Dermatology;2024-05

3. The Role of Alarmins in the Pathogenesis of Rheumatoid Arthritis, Osteoarthritis, and Psoriasis;Current Issues in Molecular Biology;2024-04-19

4. Increased tissue expression of IL-31 in patients with psoriasis;Cytokine;2024-04

5. Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis;Arthritis & Rheumatology;2024-03-04